Acta Neuropathologica

, Volume 118, Issue 3, pp 407–413 | Cite as

p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis

  • Anna Nogalska
  • Chiara Terracciano
  • Carla D’Agostino
  • W. King Engel
  • Valerie AskanasEmail author
Original Paper


p62, also known as sequestosome1, is a shuttle protein transporting polyubiquitinated proteins for both the proteasomal and lysosomal degradation. p62 is an integral component of inclusions in brains of various neurodegenerative disorders, including Alzheimer disease (AD) neurofibrillary tangles (NFTs) and Lewy bodies in Parkinson disease. In AD brain, the p62 localized in NFTs is associated with phosphorylated tau (p-tau). Sporadic inclusion-body myositis (s-IBM) is the most common progressive muscle disease associated with aging, and its muscle tissue has several phenotypic similarities to AD brain. Abnormal accumulation of intracellular multiprotein inclusions, containing p-tau in the form of paired helical filaments, amyloid-β, and several other “Alzheimer-characteristic proteins”, is a characteristic feature of the s-IBM muscle fiber phenotype. Diminished proteasomal and lysosomal protein degradation appear to play an important role in the formation of intra-muscle-fiber inclusions. We now report that: (1) in s-IBM muscle fibers, p62 protein is increased on both the protein and the mRNA levels, and it is strongly accumulated within, and as a dense peripheral shell surrounding, p-tau containing inclusions, by both the light- and electron-microscopy. Accordingly, our studies provide a new, reliable, and simple molecular marker of p-tau inclusions in s-IBM muscle fibers. The prominent p62 immunohistochemical positivity and pattern diagnostically distinguish s-IBM from polymyositis and dermatomyositis. (2) In normal cultured human muscle fibers, experimental inhibition of either proteasomal or lysosomal protein degradation caused substantial increase of p62, suggesting that similar in vivo mechanisms might contribute to the p62 increase in s-IBM muscle fibers.


Sporadic inclusion-body myositis p62/sequestosome1 (p62/SQSTM1) Inclusions Phosphorylated tau Proteasome inhibition Lysosome inhibition Cultured human muscle fibers 



Dr. Nogalska is on leave from the Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland. Dr. Terracciano was on leave from the Department of Neuroscience, University of Tor Vergata and Fondazione S. Lucia, Rome, Italy. Maggie Baburyan provided excellent technical assistance in electronmicroscopy. Margherita Simonetti participated in tissue culture experiments. We are grateful to Dr. Michael Jakowec of the USC Department of Neurology for allowing us to use his real-time PCR equipment. Supported by grants (to VA) from the National Institutes of Health (AG 16768 Merit Award), the Muscular Dystrophy Association, and The Myositis Association.


  1. 1.
    Askanas V, Engel WK (1992) Cultured normal and genetically abnormal human muscle. In: Rowland LP, Di Mauro S (eds) The handbook of clinical neurology, myopathies, vol 18. North Holland, Amsterdam, pp 85–116Google Scholar
  2. 2.
    Askanas V, Engel WK (2007) Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 19:550–559PubMedCrossRefGoogle Scholar
  3. 3.
    Askanas V, Engel WK (2008) Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer’s and Parkinson’s disease brains. Acta Neuropathol 116:583–595PubMedCrossRefGoogle Scholar
  4. 4.
    Askanas V, Engel WK (2001) Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 60:1–14PubMedGoogle Scholar
  5. 5.
    Askanas V, Engel WK, Alvarez RB (1993) Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer’s disease using fluorescence technique. Neurology 43:1265–1267PubMedGoogle Scholar
  6. 6.
    Askanas V, Engel WK, Alvarez RB, McFerrin J, Broccolini A (2000) Novel immunolocalization of alpha-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions. J Neuropathol Exp Neurol 59:592–598PubMedGoogle Scholar
  7. 7.
    Askanas V, Engel WK, Nogalska A (2009) Inclusion-body myositis: a degenerative muscle disease associated with intra-muscle-fiber multiprotein aggregates, proteasome inhibition, endoplasmic reticulum stress, and decreased lysosomal degradation. Brain Pathol 19:493–506. doi: 10.1111/j.1750-3639.2009.00290.x
  8. 8.
    Babu JR, Geetha T, Wooten MW (2005) Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 94:192–203PubMedCrossRefGoogle Scholar
  9. 9.
    Babu R, Seibenhener LM, Peng J, Strom AL, Kemppainen R, Cox N, Zhu H, Wooten MC, Diaz-Meco MT, Moscat J, Wooten MW (2008) Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. J Neurochem 106:107–120CrossRefGoogle Scholar
  10. 10.
    Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H, Johansen T (2005) p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 171:603–614PubMedCrossRefGoogle Scholar
  11. 11.
    Bjorkoy G, Lamark T, Johansen T (2006) p62/SQSTM1: a missing link between protein aggregates and the autophagy machinery. Autophagy 2:138–139PubMedGoogle Scholar
  12. 12.
    Donaldson KM, Li W, Ching KA, Batalov S, Tsai CC, Joazeiro CAP (2003) Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. Proc Natl Acad Sci USA 100:8892–8897PubMedCrossRefGoogle Scholar
  13. 13.
    Fratta P, Engel WK, McFerrin J, Davies KJ, Lin SW, Askanas V (2005) Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-β precursor protein-overexpressing cultured human muscle fibers. Am J Pathol 167:517–526PubMedGoogle Scholar
  14. 14.
    Goedert M, Jakes R, Vanmechelen E (1995) Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett 189:167–170PubMedCrossRefGoogle Scholar
  15. 15.
    Ishii T, Yanagawa T, Yuki K, Kawane T, Yoshida H, Bannai S (1997) Low micromolar levels of hydrogen peroxide and proteasome inhibitors induce the 60-kDa A170 stress protein in murine peritoneal macrophages. Biochem Biophys Res Comm 232:33–37PubMedCrossRefGoogle Scholar
  16. 16.
    Josephs KA, Lin WL, Ahmed Z, Stroh DA, Graff-Radford NR, Dickson DW (2008) Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions. Acta Neuropathol 116:159–167PubMedCrossRefGoogle Scholar
  17. 17.
    Ksiezak-Reding H, Dickson DW, Davies P, Yen SH (1987) Recognition of tau epitopes by anti-neurofilament antibodies that bind to Alzheimer neurofibrillary tangles. Proc Natl Acad Sci USA 84:3410–3414PubMedCrossRefGoogle Scholar
  18. 18.
    Kuusisto E, Kauppinen T, Alafuzoff I (2008) Use of p62/SQSTM1 antibodies for neuropathological diagnosis. Neuropathol Appl Neurobiol 34:69–80CrossRefGoogle Scholar
  19. 19.
    Kuusisto E, Salminen A, Alafuzoff I (2002) Early accumulation of p62 in neurofibrillary tangles in Alzheimer’s disease: possible role in tangle formation. Neuropathol Appl Neurobiol 28:228–237PubMedCrossRefGoogle Scholar
  20. 20.
    Kuusisto E, Salminen A, Alafuzoff I (2001) Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. NeuroReport 12:2085–2090PubMedCrossRefGoogle Scholar
  21. 21.
    Kuusisto E, Suuronen T, Salminen A (2001) Ubiquitin-binding protein p62 expression is induced during apoptosis and proteasomal inhibition in neuronal cells. Biochem Biophys Res Comm 280:223–228PubMedCrossRefGoogle Scholar
  22. 22.
    Mendell JR, Sahenk Z, Gales T, Paul L (1991) Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol 48:1229–1234PubMedGoogle Scholar
  23. 23.
    Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 96:10403–10408PubMedCrossRefGoogle Scholar
  24. 24.
    Mirabella M, Alvarez RB, Bilak M, Engel WK, Askanas V (1996) Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. J Neuropathol Exp Neurol 55:774–786PubMedCrossRefGoogle Scholar
  25. 25.
    Moscat J, Diaz-Meco MT, Wooten MW (2007) Signal integration and diversification through the p62 scaffold protein. Trends Biochem Sci 32:95–100PubMedCrossRefGoogle Scholar
  26. 26.
    Needham M, Mastaglia FL (2007) Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 6:620–631PubMedCrossRefGoogle Scholar
  27. 27.
    Nogalska A, Engel WK, McFerrin J, Kokame K, Komano H, Askanas V (2006) Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulum stress-induced cultured human muscle fibers. J Neurochem 96:1491–1499PubMedCrossRefGoogle Scholar
  28. 28.
    Nogalska A, Wojcik S, Engel WK, McFerrin J, Askanas V (2007) Endoplasmic reticulum stress induces myostatin precursor protein and NF-κB in cultured human muscle fibers: relevance to inclusion body myositis. Exp Neurol 204:610–618PubMedCrossRefGoogle Scholar
  29. 29.
    Nukina N, Kosik KS, Selkoe DJ (1987) Recognition of Alzheimer paired helical filaments by monoclonal neurofilament antibodies is due to crossreaction with tau protein. Proc Natl Acad Sci USA 84:3415–3419PubMedCrossRefGoogle Scholar
  30. 30.
    Ohkuma S, Poole B (1978) Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 75:3327–3331PubMedCrossRefGoogle Scholar
  31. 31.
    Olivé M, van Leeuwen FW, Janué A, Moreno D, Torrejón-Escribano B, Ferrer I (2008) Expression of mutant ubiquitin (UBB + 1) and p62 in myotilinopathies and desminopathies. Neuropathol Appl Neurobiol 34:76–87PubMedGoogle Scholar
  32. 32.
    Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, Overvatn A, Bjorkoy G, Johansen T (2007) p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 282:24131–24145PubMedCrossRefGoogle Scholar
  33. 33.
    Scott IS, Lowe JS (2007) The ubiquitin-binding protein p62 identifies argyrophilic grain pathology with greater sensitivity than conventional silver stains. Acta Neuropathol 113:417–420PubMedCrossRefGoogle Scholar
  34. 34.
    Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW (2004) Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 24:8055–8068PubMedCrossRefGoogle Scholar
  35. 35.
    Terracciano C, Nogalska A, Engel WK, Wojcik S, Askanas V (2008) In inclusion-body myositis muscle fibers Parkinson-associated DJ-1 is increased and oxidized. Free Radic Biol Med 45:773–779PubMedCrossRefGoogle Scholar
  36. 36.
    Yang CC, Alvarez RB, Engel WK, Askanas V (1996) Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis. NeuroReport 8:153–158PubMedCrossRefGoogle Scholar
  37. 37.
    Yang CC, Askanas V, Engel WK, Alvarez RB (1998) Immunolocalization of transcription factor NF-kappaB in inclusion-body myositis muscle and at normal human neuromuscular junctions. Neurosci Lett 254:77–80PubMedCrossRefGoogle Scholar
  38. 38.
    Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, Kleinert R, Prinz M, Aguzzi A, Denk H (2002) p62 is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 160:255–263PubMedGoogle Scholar
  39. 39.
    Zheng-Fischhèofer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E (1998) Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem 252:542–552CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Anna Nogalska
    • 1
  • Chiara Terracciano
    • 1
  • Carla D’Agostino
    • 1
  • W. King Engel
    • 1
  • Valerie Askanas
    • 1
    Email author
  1. 1.Department of Neurology, USC Neuromuscular CenterGood Samaritan Hospital, University of Southern California Keck School of MedicineLos AngelesUSA

Personalised recommendations